Anika Therapeutics Ownership
| ANIK Stock | USD 15.42 0.20 1.28% |
Shares in Circulation | First Issued 1993-03-31 | Previous Quarter 14.8 M | Current Value 14.4 M | Avarage Shares Outstanding 11.5 M | Quarterly Volatility 3.8 M |
Anika |
Anika Stock Ownership Analysis
About 90.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.47. Some equities with similar Price to Book (P/B) outperform the market in the long run. Anika Therapeutics recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts. Anika Therapeutics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 297 people. For more info on Anika Therapeutics please contact the company at 781 457 9000 or go to https://www.anika.com.Besides selling stocks to institutional investors, Anika Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Anika Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Anika Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Anika Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Anika Therapeutics Insider Trades History
Roughly 4.0% of Anika Therapeutics are currently held by insiders. Unlike Anika Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Anika Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Anika Therapeutics' insider trades
Anika Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anika Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anika Therapeutics backward and forwards among themselves. Anika Therapeutics' institutional investor refers to the entity that pools money to purchase Anika Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stonepine Capital Management Llc | 2024-12-31 | 238.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 189.2 K | Meros Investment Management, Lp | 2024-12-31 | 177.7 K | D. E. Shaw & Co Lp | 2024-12-31 | 153.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 137.5 K | Northern Trust Corp | 2024-12-31 | 123.2 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 119 K | Globeflex Capital, L.p. | 2024-12-31 | 87.6 K | Jpmorgan Chase & Co | 2024-12-31 | 82.5 K | Trigran Investments Inc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Anika Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anika Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anika Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anika Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anika Therapeutics' latest congressional trading
Congressional trading in companies like Anika Therapeutics, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Anika Therapeutics by those in governmental positions are based on the same information available to the general public.
| 2021-03-05 | Representative Tom Malinowski | Acquired Under $15K | Verify |
Anika Therapeutics Outstanding Bonds
Anika Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anika Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anika bonds can be classified according to their maturity, which is the date when Anika Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ANHEUSER BUSCH INC Corp BondUS035229CQ41 | View | |
| US035229DA89 Corp BondUS035229DA89 | View | |
| US035229CG68 Corp BondUS035229CG68 | View | |
| ABIBB 68 20 AUG 32 Corp BondUS035229CJ08 | View | |
| ANHEUSER BUSCH INC Corp BondUS035229DC46 | View | |
| US03523TAP30 Corp BondUS03523TAP30 | View | |
| ANHEUSER BUSCH INBEV Corp BondUS03523TBW71 | View | |
| ANHEUSER BUSCH INBEV Corp BondUS03523TBV98 | View |
Anika Therapeutics Corporate Filings
F4 | 18th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 17th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 12th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of February 2025 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anika Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.